FLNA FILANA THERAPEUTICS, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.49

Period return

-1.40 (-48.44%)

Volume

545.6K

2026-06-01O $1.54 H $1.6 L $1.49 C $1.49MA5 $1.5MA20 $1.34MA60 $1.62MA120 $1.94

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2025. 10. 06.MediumBUY8 months ago
LUCID CAPITAL MARKETS: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $6.5 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Sector: Healthcare
Industry: Biotechnology
HQ: Austin, TX, United States
Fiscal year end: —
Employees: 17
IPO date: —

View details →

Top news

Stored first · Google News · Yahoo Finance (English)

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 05. 07.	After market close (AMC)	—	—	—	$0	—	Scheduled

Date	Firm	Analyst	Action	Rating change	Price target	Report
2025. 10. 06.	LUCID CAPITAL MARKETS	—	Initiate coverage	— → Buy	—	LUCID CAPITAL MARKETS: Buy

Available on Pro+

See full research history

Compare a firm's past rating changes and its actions on other stocks in the same sector.

View plans

Key stats

As of FY2026Q1 · Source: SEC/DART + price data

Market cap$74.39M

Shares out.48M

PER1.77x

EPS (TTM)$0.87

PBR0.51x

BPS$3.02

Dividend/share—

Dividend yield—

ConsensusStrong buy

Price target$6.50+322.1%

Target range$5.00 ~ $8.00· 2 analysts

Available on Premium+

See the key changes, summarized by AI

Filings, earnings, and institutional changes summarized in one paragraph, with source links.

View plans

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,988,814	$3.36B	0.00%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	39,121	$66.11M	0.00%	—	New position

Available on Pro+

See all institutional holding changes

See new positions, full exits, and weight changes.

View plans